Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis

Abstract

Abstract, Results, line 2 which previously read: Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04).Should read: Although median tumor size was similar between groups, the median tumor number was significantly higher in the S-TACE versus TACE-alone group (7 vs. 4, P \ 0.01).Page 751, Abstract, Results, line 9 which previously read:Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone.Should read: Median PFS (189 vs. 106 days, P \ 0.01) and median overall survival time (861 vs. 467 days, P \ 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Of the 95 patients, 24 patients who were previously nonresponsive responsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).Should read: Of the 95 patients, 24 patients who were previously nonresponsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).Page 754, Section 3, 2nd column, line 10 which previously read:The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE ( Should read:The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (3 [range 2-4] vs. 2 [range 2-3], P \ 0.01) and radiofrequency ablation (4 [range 1-5] vs. 1 [range 0-3], P \ 0.01).

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

“…In addition, further analysis showed that tumor size ≥7 cm was also associated with poorer OS and PFS. These findings are in agreement with previous investigations that have identified Child-Pugh class, vascular invasion, tumor size, as well as BCLC stage, Eastern Cooperative Oncology Group (ECOG) performance status and alanine transaminase, as independent predictors of prognosis [ 47 – 49 ]. Although the tumor number and tumor size are both recognized as being associated with prognosis [ 50 ], a recent study has suggested that total tumor volume may be a better predictor of outcomes [ 51 ].…”

Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index

“…We previously reported that the therapeutic strategy of early switching to sorafenib with TACE as a maintenance therapy prolonged progression-free survival (PFS) compared with repeated conventional TACE monotherapy in HCC patients unresponsive to TACE [ 23 , 24 ]. In the present study, we employed an index obtained by dividing the total number of radiofrequency ablation (RFA), TACE, and transcatheter arterial infusion (TAI) procedures by the years of survival to evaluate the efficacy of repeated TACE monotherapy and early switching from TACE to sorafenib therapy on OS.…”

Hepatocellular Carcinoma (HCC): Epidemiology, Risk Factors, and Survival

“…Ohki T et al found that median overall survival time (861 vs. 467 days, P = 0.01) from the time of nonresponsiveness to TACE were signi cantly longer with TACE followed by sorafenib within 14 days than TACE alone. (27) Kaplan-Meier survival curve analysis was done using log-rank test for possible risk factors for survival period and hazards ratios with 95% con dence interval and it was observed that of all risk factors highest hazard was found with a multifocal lesion (2.0577) and results were signi cantly higher than unifocal lesion (95 % con dence interval: 0.9225 to 4.5900, p 0.0451) with median survival period of 7 vs 9.5 months. Similarly, it was observed in the present study that age < 59 years, KPS ≤ 60, male gender, alcoholic, HbsAg reactive, presence of portal vein thrombosis had 1.0933, 1.8792, 1.8267, 1.2647, 0.8182, and 1.2749 times more hazard as compared to age ≥ 59 years, KPS > 60, female gender, non-alcoholic, HbsAg non-reactive and absence of portal vein thrombosis with a median survival period of 7 vs 7.5 months, 6.5 vs 8 months, 7 vs 9.5 months, 7 vs 8 months, 7 vs 7.5 months, 6.5 vs 8 months respectively.…”